New data on Antaros’ platelet-derived growth factor receptor beta (PDGFRβ) positron emission tomography (PET) tracer for fibrogenesis was presented earlier this month at the European Association of Nuclear Medicine (EANM) Congress 2025.
Fibrosis is a common pathway in many diseases affecting organs such as the liver, kidney, and heart. The need for non-invasive and sensitive biomarkers that can detect changes in fibrosis development and therefore be used to assess response to interventions is high.
ATH001 is a radiopharmaceutical that is being developed to probe the presence of PDGFRβ using PET imaging. PDGFRβ is a marker of ongoing fibrogenesis in tissue. ATH001 enables tissue specific quantification of active fibrotic disease and shows strong promise as a non-invasive tool for imaging fibrogenesis and could provide valuable insights in the search for new treatments for fibrotic diseases including metabolic dysfunction-associated steatohepatitis (MASH), primary sclerosing cholangitis (PSC) and fibrostenotic Crohn’s disease.
New data around the ATH001 probe for fibrogenesis was presented by Uppsala University at the EANM’25 October 4-8 in Barcelona. Find the abstract information below:
Title: Dosimetry and safety of the PDGFRb PET tracer [68Ga]GaDOTA-Cys-ATH001: first-in-human data in patients with liver fibrosis and healthy subjects
Abstract number: EP-1104
Authors: Lubberink M, Lohith TG, Derdak Z, Wilkens P, Wennbo H, Palmer E, Ramolli A, Mitran B, Abouyzayed A, Johansson L, Rorsman F, Vessby J, Eriksson O
Title: Ga-68 labelled Affibody molecule based radiopharmaceutical targeting platelet derived growth factor receptor beta detects active fibrosis in patients with myocardial infarction.
Abstract number: OP-728
Authors: Velikyan I, Grinnemo K, Flodin V, James S, Thelander U, Korsgren O, Eriksson O
Title: Optimization of an Affibody molecule construct for PDGFRb-targeted theranostics
Abstract number: EP-0137
Authors: Mallapura M, Abouzayed A, Olsson H, Xiong M, Korsgren O, Löfblom J, Wagner M, Eriksson O
About Antaros Tracer
Antaros Tracer is a sister company to Antaros Medical, formed to ensure an expedited and focused development of new Positron Emission Tomography (PET) tracers to be used as important biomarkers in drug development studies. Current disease area focus is fibrotic disease and immune-system activation in immune-oncology, inflammatory disease, and immunology.
For more information: Antaros Tracer
About Antaros Medical
Antaros Medical is in the forefront of imaging solutions for drug development, combining imaging expertise with extensive knowledge in drug development and disease biology to design and deliver clinical trials for decision-making and differentiation. With global collaborations with pharmaceutical companies across metabolic, fibrotic and inflammatory diseases, Antaros Medical is providing key answers in every stage of drug development, from early to late-stage clinical trials. Antaros Medical’s headquarter and CoreLab is based in Sweden, with a subsidiary in the US.
For more information: Imaging the future – Antaros Medical